UCLA Health Jonsson Comprehensive Cancer Center | Strategic Alliance Partners

Latest from UCLA Health Jonsson Comprehensive Cancer Center

TTX-030 Plus Budigalimab/mFOLFOX6 Induces Responses in PD-L1–Low Advanced Gastric/GEJ Cancer

April 12, 2022

The addition of the investigational anti-CD39 antibody TTX-030 to frontline treatment with the PD-L1 inhibitor budigalimab and mFOLFOX6 was determined to be safe and tolerable in patients with locally advanced or metastatic HER2-negative gastroesophageal junction adenocarcinoma.

Hurvitz Highlights Practice-Changing DESTINY-Breast03 Data in HER2+ Metastatic Breast Cancer

April 08, 2022

Sara A. Hurvitz, MD, medical oncologist and medical director at the Jonsson Comprehensive Cancer Center Clinical Research Unit, discussed pivotal findings in the HER2-positive treatment landscape that possess the potential to change practice.

Risk-Adaptive Approaches Offer Safer, Effective Strategies for Early-Stage HER2+ Breast Cancer

March 05, 2022

The integration of HER2-targeted therapies into the treatment paradigm for patients with early-stage breast cancer, specifically the standard trastuzumab, has shifted focus away from whether patients should receive to how and when they should receive treatment with these agents.

Hurvitz Reviews Pivotal Data From 2021, Previews Year Ahead in HER2+ Metastatic Breast Cancer

March 03, 2022

Dr Hurvitz sheds light on shifts in practice patterns in HER2-positive breast cancer in light of data that emerged in 2021, remaining questions regarding treatment sequencing, the importance of updates to the National Comprehensive Cancer Network guidelines in metastatic HER2-positive breast cancer, and future directions to keep an eye on in 2022.

Frontline Pembrolizumab Monotherapy, Plus Chemo Shows Mixed OS Findings in PD-L1+ Gastric/GEJ Adenocarcinoma

January 20, 2022

Although pembrolizumab monotherapy showed noninferiority to chemotherapy for overall survival in patients with advanced gastric or gastroesophageal junction adenocarcinoma and a PD-L1 combined positive score of 1 or higher, and a clinically meaningful benefit over chemotherapy in those with a CPS of 10 or higher, pembrolizumab plus chemotherapy failed to show superiority over chemotherapy alone in either subset.

ADXS-503 Plus Pembrolizumab Shows Early Clinical Benefit, Safety in Metastatic NSCLC

January 13, 2022

The addition of ADXS-503 to the treatment of patients with metastatic non–small cell lung cancer who were progressing on pembrolizumab (Keytruda) resulted in encouraging responses and durable disease control, according to findings from the phase 1/2 trial.

Addition of ADT to Radiation, and Prolonged ADT, Provide Clinical Benefit in Localized Prostate Cancer

November 08, 2021

The use of androgen deprivation therapy and prolongation of adjuvant ADT to at least 18 months in conjunction with definitive radiotherapy provides clinically meaningful benefit for patients with localized prostate cancer, irrespective of radiation dose.